Results 201 to 210 of about 159,989 (316)

Artificial recombinant high-density protein nanocarriers for precision drug delivery. [PDF]

Chem Sci
Li W, Jia N, Li M, Jiang Y, Lu J.
europepmc   +1 more source

Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer's disease

Brain Pathology, EarlyView.
Neuritic plaques increase in the intermediate stage of Alzheimer's neuropathological change. The intermediate stage of Alzheimer's disease was investigated by transcriptomics and immunohistochemistry. This revealed that inflammasome sensors NLRP1, NLRP3, and AIM2 oligomerize with ASC speck to form the inflammasome complex and initiate the downstream ...
Juan Pablo de Rivero Vaccari, David A. Davis, Andrew P. Sawaya, Susanna P. Garamszegi, Xiaoyan Sun, Ayled Barreda, Helen M. Bramlett, Sakir Humayun Gultekin, W. Dalton Dietrich, Robert W. Keane, Regina T. Vontell   +10 more
wiley   +1 more source

Predictive lipidaemic and clinical factors for PVR formation after RRD surgery in nondiabetic patients. [PDF]

Int J Ophthalmol
Jiang Y, Niu T, Lan GH, Xu YP, Liu K.
europepmc   +1 more source

Data‐driven thresholds for standardized classification of severe Alzheimer's disease neuropathology using digital neuropathology

Brain Pathology, EarlyView.
We generated digital pathologic algorithms (AI‐based modules that can be freely shared) to: optimize the sampling (ROI) for diagnosis of ADNC‐related tau pathology; compare/transition between Aperio and HALO platforms; and rationalize severe Braak NFT staging, so that all Braak‐VI cases had dementia, and all Braak‐V cases had MCI or dementia.
Ryan K. Shahidehpour, Allison M. Neltner, Mitchell A. Klusty, Cole Corbett, Angelique D. Gonzalez, David A. Gutman, David W. Fardo, Adam D. Bachstetter, Cody Bumgardner, Margaret E. Flanagan, Peter T. Nelson   +10 more
wiley   +1 more source

Apolipoprotein [PDF]

, 2018
K. J. Lackner, D. Peetz
openaire   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Apolipoprotein A-IV Cardiac Amyloidosis Diagnosed by Mass Spectrometry-Based Proteomic Analysis. [PDF]

JACC Case Rep
Masutani Y, Onoue K, Soeda T, Nakano T, Sakaguchi Y, Endo J, Shintani-Domoto Y, Kanamori H, Kametani F, Hikoso S, Kawata H.   +10 more
europepmc   +1 more source

Effects of Common Food Additives Kappa‐, Iota‐ and Lambda‐Carrageenans on Intestinal Epithelial Cell Activation and Barrier Disruption

Clinical &Experimental Allergy, EarlyView.
Carrageenans, widely used food additives, disrupted intestinal epithelial integrity in a gut‐on‐a‐chip model. All types (κ‐, ɩ‐, λ‐) induced cytotoxicity, inflammation and tight junction (TJ) disruption, triggering TNF‐mediated immune responses. λ‐Carrageenan had the most severe effects, supporting the Epithelial Barrier Theory linking food additives ...
Na Sun, Yagiz Pat, Huseyn Babayev, Sena Ardicli, Ismail Ogulur, Xianting Bu, Manru Li, Shuqi Jia, Beate Rückert, Raja Dhir, Kari C. Nadeau, Mubeccel Akdis, Cezmi A. Akdis, Duygu Yazici   +13 more
wiley   +1 more source

Association of Serum Albumin and the ApoB/ApoA1 Ratio with Acute Post-Stroke Cognitive Impairment: A Propensity Score-Matched Case-Control Study. [PDF]

Int J Gen Med
Liu D, Zhang J, Wei X, Zhang S, Yan F.
europepmc   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source